<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04435067</url>
  </required_header>
  <id_info>
    <org_study_id>PACT32</org_study_id>
    <nct_id>NCT04435067</nct_id>
  </id_info>
  <brief_title>Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)</brief_title>
  <acronym>LUMACA</acronym>
  <official_title>Retrospective Observational Study on Patients With Lung Metastases From Pancreatic Adenocarcinoma: Evaluation of Clinical Features and Correlation With Molecular and Radiomics Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the characterization from epidemiological, radiomics and molecular
      point of view of lung metastasis of patients at beginning affected by pancreatic
      adenocarcinoma (PDAC), which after the resection of primitive tumor have met with initial
      recurrence of the disease exclusively at the lung level.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical surgical treatment of primitive PDAC, associated with adjuvant cancer treatments, is
      possible only in 15-20% of patients, and, to date, represents the best therapeutic strategy.
      Nevertheless, remote recurrence is frequent after radical surgical treatment of primitive
      neoplasia. Among the main locations of metastasis from PDAC, the lung represent the second
      metastatic location with a better prognosis than other remote metastasis. Surgical treatment
      of lung metastasis has a consolidated role in the treatment of other neoplasms such as
      sarcomas, colorectal and renal neoplasms while in the context of PDAC the resection of lung
      metastases is a rather rare and also debated event.

      In absence of consolidated data on the results of surgical treatment and on the clinical
      outcomes of patients with lung metastasis from PDAC the investigators designed this
      retrospective observational study in order to analyze the clinical and pathological
      characteristics of patients suffering from lung metastasis from PDAC treated at San Raffaele
      Hospital in a period between 2008 and 2019. To this purpose, the investigators will analyze
      and compare two patient cohorts: 1-patients in whom lung metastasis were resected for
      therapeutic purposes; 2-patients in whom lung metastasis were removed for diagnostic purposes
      only.

      An analysis of genetic mutations and the gene expression profile of lung metastasis and
      primary neoplasia will also be performed to evaluate any predictive elements of lung
      metastasis and the prognostic role of these mutations.

      In parallel, the investigators will perform radiomics analysis on TAC imaging at diagnosis of
      lung metastasis and, if possible, of the primary tumor.

      All the data necessary for the completion of the study were collected as part of the usual
      outpatient visits in the appropriate outpatient medical records and include: date of birth,
      date of diagnosis, gender, performance status, stage of the disease, comorbidity, concomitant
      chronic therapies, level of tumor markers (CEA and Ca19.9) before treatment and variations
      during therapy, type of chemotherapy, start and end date of chemotherapy, number of cycles,
      possible dosage reduction of the drugs used in the various chemotherapy regimes, dates and
      results of instrumental revaluations according to RECIST 1.1, main chemotherapy toxicities
      and grade according to CTCAE 5.0, date and type of surgery, mutation analysis results and
      last follow-up date. In the event of death, the dates of death are communicated by the
      registry office of the municipality of residence of the patient, according to the official
      procedure. All data will be collected in an electronic database in coded form
      (pseudonymization).

      Power size calculation:

      All patients who meet the inclusion and exclusion criteria and who have been treated at the
      Medical Oncology and Thoracic Surgery Units of the San Raffaele Hospital between 2008 and
      2019 will be taken into consideration, for a total of 44 patients. To identify predictive
      and/or prognostic clinical and pathological factors that can influence the outcome of these
      patients, the two cohorts described above will be analyzed and compared through univariate
      and multivariate analyzes. Overall survival (OS) and progression-free survival (PFS) will
      also be assessed using the Kaplan Meier method and the long-rank test will be used to compare
      OS and PFS between the two cohorts under study. All tests will be double-tailed and a p &lt;0.05
      will be considered significant. The ninety-five percent confidence intervals (CI) will be
      calculated to assess the accuracy of the estimates obtained.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and pathological features of lung metastasis</measure>
    <time_frame>6 months</time_frame>
    <description>Analyze the clinical and pathological characteristics of the two cohorts of patients affected by lung metastasis from PDAC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular and radiomics features of lung metastasis</measure>
    <time_frame>18 months</time_frame>
    <description>Correlate the pathological characteristics of the two cohorts of patients affected by lung metastasis from PDAC with radiomics and molecular features, in order to identify prognostic and/or predictive factors related to lung metastasis in the PDAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences between the two cohorts</measure>
    <time_frame>18 months</time_frame>
    <description>Highlight any differences between the two cohorts of patients examined</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pancreas Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>patients in whom lung metastasis were resected for therapeutic purposes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>patients in whom lung metastasis were removed for diagnostic purposes only</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia</intervention_name>
    <description>The mutational analysis of the main oncogenes and tumor suppressor genes involved in the genesis and tumor progression will be performed on the genomic DNA extracted from each sample using the Ion Torrent TM Oncomine TM Comprehensive Assay version 3 (OCAv3) kit. This panel includes 161 cancer-related genes and allows the identification of all genomic alterations affecting oncogenes and recurrently altered tumor suppressor genes in solid tumors. The study of gene expression will be carried out using Nanostring Technology using the Pancancer IO 360 TM panel which allows simultaneous analysis for each sample of multiple mRNAs associated with crucial pathways in carcinogenesis and the immunological profile of the tumor, defining its up and down conditions gene regulation.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor</intervention_name>
    <description>This study will be performed using the SPAARC IBSI (International Biomarker Standardization Initiative) compliant software implemented in the MatLab environment (MathWorks, Boston, USA) through several steps: (a) CT imaging retrieval, (b) image segmentation and rendering, (c) feature extraction and (d) qualification/quantification. Approximately 200 radiomics characteristics will be extracted, such as: Morphology, Statistical, Intensity Histogram, Gray Level Co-occurrence Matrix 3D_average, Gray Level Co-occurrence Matrix 3D_combined, Gray Level Run Length 3D_average, Gray Level Run Length 3D_combined, Gray Level Size Zone Matrix 3D, Neighbor Gray Tone Difference Matrix 3D, Gray Level Distance Zone Matrix 3D.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from histological samples fixed in formalin and included in paraffin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a confirmed diagnosis of lung metastasis from PDAC from 2008 to 2019
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cytological/histological diagnosis of pancreatic adenocarcinoma as a primary tumor and
             localization of adenocarcinoma compatible with pancreatic primitivity for lung
             metastasis;

          -  Previous surgical resection of the primary tumor;

          -  Exclusive presence of single or multiple lung metastasis at disease recurrence;

          -  Radical or diagnostic excision of lung metastasis;

          -  Informed patient consent (for currently living patients).

        Exclusion Criteria:

          -  Patients not undergoing lung resection surgery for diagnostic and/or therapeutic
             purposes for cardiac or respiratory functional contraindication.

          -  Patients with lung metastases synchronous with primary cancer. Contacts and Locations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michele Reni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCSS Raffaele</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giulia Orsi, MD</last_name>
    <phone>+390226437602</phone>
    <email>orsi.giulia@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Maddalena Valente, PhD</last_name>
    <phone>+390226437623</phone>
    <email>valente.mariamaddalena@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IRCCS San Raffaele Diagnostic Radiology Unit</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco De Cobelli, Prof.</last_name>
      <phone>+390226433434</phone>
      <email>decobelli.francesco@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Diego Palumbo, MD</last_name>
      <phone>+390226432388</phone>
      <email>palumbo.diego@hsr.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Medical Oncology Unit</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Orsi, MD</last_name>
      <phone>+39 02 26437602</phone>
      <email>orsi.giulia@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Maria Maddalena Valente, PhD</last_name>
      <phone>+39 02 26437623</phone>
      <email>valente.mariamaddalena@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Michele Reni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Pathological Anatomy Unit</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Doglioni, Prof.</last_name>
      <phone>+390226432511</phone>
      <email>doglioni.claudio@hsr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Thoracic Surgery Unit</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giampiero Negri, Prof.</last_name>
      <phone>+390226437128</phone>
      <email>negri.giampiero@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Angelo Carretta, MD</last_name>
      <phone>+390226437132</phone>
      <email>carretta.angelo@hsr.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL, Meneshian A, Yang SC, Wolfgang CL. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011 Sep;15(9):1611-7. doi: 10.1007/s11605-011-1605-8. Epub 2011 Jul 2.</citation>
    <PMID>21725701</PMID>
  </reference>
  <reference>
    <citation>Ceppa DP. Results of Pulmonary Resection: Sarcoma and Germ Cell Tumors. Thorac Surg Clin. 2016 Feb;26(1):49-54. doi: 10.1016/j.thorsurg.2015.09.007. Review.</citation>
    <PMID>26611510</PMID>
  </reference>
  <reference>
    <citation>Okui M, Yamamichi T, Asakawa A, Harada M, Horio H. Resection for Pancreatic Cancer Lung Metastases. Korean J Thorac Cardiovasc Surg. 2017 Oct;50(5):326-328. doi: 10.5090/kjtcs.2017.50.5.326. Epub 2017 Oct 5.</citation>
    <PMID>29124023</PMID>
  </reference>
  <reference>
    <citation>Rama N, Monteiro A, Bernardo JE, Eug√©nio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors. Eur J Cardiothorac Surg. 2009 Mar;35(3):444-9. doi: 10.1016/j.ejcts.2008.10.047. Epub 2009 Jan 10.</citation>
    <PMID>19136273</PMID>
  </reference>
  <reference>
    <citation>Yamashita K, Miyamoto A, Hama N, Asaoka T, Maeda S, Omiya H, Takami K, Doki Y, Mori M, Nakamori S. Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma. Dig Surg. 2015;32(6):464-71. doi: 10.1159/000439545. Epub 2015 Oct 31.</citation>
    <PMID>26517228</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 14, 2020</study_first_submitted>
  <study_first_submitted_qc>June 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS San Raffaele</investigator_affiliation>
    <investigator_full_name>Michele Reni</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Pancreas Adenocarcinoma</keyword>
  <keyword>Lung Metastasis</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>Molecular analysis</keyword>
  <keyword>Radiomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

